Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) saw strong trading volume on Thursday . 369,693 shares traded hands during trading, an increase of 109% from the previous session’s volume of 177,106 shares.The stock last traded at $8.17 and had previously closed at $7.42.

Several research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price target on shares of Foamix Pharmaceuticals in a research note on Tuesday, May 10th.

The company’s market cap is $250.47 million. The firm’s 50-day moving average price is $6.58 and its 200 day moving average price is $6.54.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.08. On average, equities research analysts expect that Foamix Pharmaceuticals Ltd. will post ($0.89) EPS for the current year.

A hedge fund recently raised its stake in Foamix Pharmaceuticals stock. J. Goldman & Co LP raised its stake in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 22.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 580,000 shares of the specialty pharmaceutical company’s stock after buying an additional 105,190 shares during the period. J. Goldman & Co LP owned 1.90% of Foamix Pharmaceuticals worth $4,704,000 at the end of the most recent quarter.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.